-
ASCO Voice of China | Prof. Yinying Wu Reviews Advances in Gastrointestinal Oncology: RAS-Targeted Therapy Reaches a Milestone as Multiple Chinese Original Studies Take Center Stage
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in grand fashion in Chicago, showcasing numerous highlights and breakthroughs in gastrointestinal oncology. On this occasion, Oncology Frontier invited Prof. Yinying Wu from the First Affiliated Hospital of Xi’an Jiaotong University to share her perspectives and discuss the impressive contributions of Chinese investigator-initiated…
-
CGOG 2026 Day 4 | Precision Translational Medicine Forum
Following the successful online sessions held during the first three days of the CGOG Annual Meeting, including six ASCO Highlights sessions and six thematic symposia, the on-site program officially commenced on June 12. On Day 4 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting, two parallel forums attracted strong interest from…
-
CGOG 2026 Day 4 | Cell and Gene Therapy Forum
Among them, the Cell and Gene Therapy Forum focused on cutting-edge advances and clinical translation in cell and gene therapies. The session brought together leading Chinese experts and scholars for…
-
CGOG 2026 Day 5 Finale | Hepatobiliary and Pancreatic Tumors Forum Successfully Concludes
The 16th Peking University Gastrointestinal Oncology Forum and the 2026 Annual Meeting of the Chinese Gastrointestinal Oncology Cooperative Group (CGOG) were successfully held in Beijing from June 9 to 13, 2026.
-
“Addition and Subtraction” in the Era of Precision Chemotherapy: Optimization Pathways for High-Risk HR+/HER2- Breast Cancer Chemotherapy Strategies Based on the WSG Pooled Analysis
In the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, the choice of chemotherapy regimen, timing of administration (neoadjuvant vs. adjuvant), and optimization of dose density remain focal points of clinical debate for biologically high-risk patients. In a recent academic conference, Professor Oleg Gluz from the West German Study Group (WSG)…
-
A New Breakthrough in Adjuvant Endocrine Therapy: lidERA Study Confirms Giredestrant Significantly Improves iDFS in Pre/Postmenopausal HR+ Early Breast Cancer
At the recent 2026 ASCO Annual Meeting, Professor Peter Schmid, representing the lidERA study group from the Barts Cancer Institute, Queen Mary University of London, detailed the efficacy and safety analysis results based on menopausal status (pre/perimenopausal vs. postmenopausal) from the Phase III lidERA BC clinical trial. The study aims to evaluate the clinical value…
-
Regardless of Trop-2, BRCA, or HER2 Status, SG plus Pembrolizumab Significantly Improves PFS in 1L PD-L1+ mTNBC Patients: Subgroup Analysis of the ASCENT-04 Study
At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Sara M. Tolaney from Dana-Farber Cancer Institute and Harvard Medical School, representing the research team, presented the latest exploratory analysis results of the ASCENT-04 study (NCT04612127). This analysis delved into the impact of biomarkers—Trop-2 expression levels, BRCA mutation status, and HER2 expression status—on…
-
CGOG 2026 Day 5 Finale | Colorectal Cancer Forum Successfully Held
The 16th Peking University Gastrointestinal Oncology Forum and the 2026 Annual Meeting of the Chinese Gastrointestinal Oncology Cooperative Group (CGOG) were successfully held in Beijing from June 9 to 13, 2026.
Connecting Medical Expertise through Media